The Trump administration suggested a 20% tax on imports from Mexico could pay for a wall along the southern border aimed at stopping illegal immigration.
Two disruptors in the group purchasing sector announced growth in their membership this week. But hospitals' use of GPOs makes it hard to determine who's winning the business.
The now-completed merger of medical device giants Abbott Laboratories and St. Jude Medical will help hospitals streamline their procurement efforts, but vendor consolidation could also lead to higher supply costs.
The prices paid for X-ray systems that can be wheeled up to a surgical table or patient bed to gather images during a procedure surged this fall as providers upgraded to 3-D-compatible equipment.
Virginia prison officials have paid a secret compounding pharmacy $66,000 to obtain lethal injection drugs for its next two executions — roughly 63 times last year's going price for the state's three-drug lethal injection package.
Premier is buying out two group purchasing organizations owned by the Greater New York Hospital Association that serve non-acute providers.
Why quality of patient care and patient experience are equally as vital of components for value-for-service based models as cost is.
Quest Diagnostics will expand a program that allows consumers to order certain lab tests without a doctor's order. It's a response to the growing trend of consumers taking charge of their healthcare.
Premier reported a rise in its fiscal 2017 first-quarter results thanks to growing revenue across both its supply chain and performance improvement services. CEO Susan DeVore also announced the launch of a new analytics product geared toward physicians.
More hospitals have worked to eliminate antibiotics in the meat they serve in patient meals in an effort to address concerns about the rise of antimicrobial-resistant pathogens.
Intermountain Healthcare's supply chain chief will take his talents to Pensiamo, a supply chain venture recently formed by UPMC and IBM.
The developer of the Auvi-Q, a previously failed competitor to the EpiPen, will bring back the “talking” epinephrine auto-injector to the market in the first half of 2017, amid public backlash against EpiPen maker Mylan.